Journal
NATURE REVIEWS UROLOGY
Volume 15, Issue 10, Pages 595-597Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41585-018-0074-1
Keywords
-
Categories
Funding
- Genentech/Roche
- AstraZeneca
- Bristol-Myers Squibb (BMS)
- Seattle Genetics
- Merck
- Bayer
- EMD Serono
- Astellas
- Mirati Research
- Novartis
- BMS
Ask authors/readers for more resources
The European Medicines Agency (EMA) and FDA have recently restricted the indications for first-line pembrolizumab and atezolizumab to patients with programmed cell death 1 ligand 1 (PD-L1)-high advanced urothelial carcinoma, a decision made following interim analyses from the ongoing Keynote-361 and IMvigor130 phase III trials. Questions remain on the magnitude of inferior survival and standardized implementation of PD-L1 testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available